Background & Aims
Abbreviations used in this paper:AE (adverse event), ANC (absolute neutrophil count), CDAI (Crohn’s Disease Activity Index), CI (confidence interval), CRP (C-reactive protein), HDL (high-density lipoprotein), IBDQ (Inflammatory Bowel Disease Questionnaire), JAK (Janus kinase), LDL (low-density lipoprotein), SAE (serious adverse event), TNF (tumor necrosis factor)
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Crohn's disease.Lancet. 2012; 380: 1590-1605
- American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.Gastroenterology. 2006; 130: 940-987
- A qualitive analysis of kinase inhibitor selectivity.Nat Biotechnol. 2008; 26: 127-132
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.J Inflamm. 2010; 7: 41
- Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.N Engl J Med. 2012; 367: 495-507
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study.Br J Dermatol. 2012; 167: 668-677
- Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.N Engl J Med. 2012; 367: 616-624
- Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.Am J Transplant. 2012; 12: 2446-2456
- Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.Gastroenterology. 1976; 70: 439-444
- Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group.Gastroenterology. 1994; 106: 287-296
- A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease.Gastroenterology. 2004; 126: 1257-1269
- A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.N Engl J Med. 1997; 337: 1029-1035
- Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.Gastroenterology. 2006; 130: 323-333
- Certolizumab pegol for the treatment of Crohn's disease.N Engl J Med. 2007; 357: 228-238
- Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.Ann Intern Med. 2007; 146: 829-838
- Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.Clin Gastroenterol Hepatol. 2011; 9: 670-678
Conflicts of interest The authors disclose the following: William Sandborn has received consulting fees from Abbott, ActoGeniX NV, AGI Therapeutics, Inc, Alba Therapeutics Corp, Albireo, Alfa Wasserman, Amgen, AM-Pharma BV, Anaphore, Astellas, Athersys, Inc, Atlantic Healthcare, Ltd, Aptalis, BioBalance Corp, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Celek Pharmaceuticals, Cellerix SL, Cerimon Pharmaceuticals, ChemoCentryx, CoMentis, Cosmo Technologies, Coronado Biosciences, Cytokine Pharmasciences, Eagle Pharmaceuticals, EnGene, Inc, Eli Lilly, Enteromedics, Exagen, Diagnostics, Inc, Ferring Pharmaceuticals, Flexio Therapeutics, Inc, Funxional Therapeutics, Ltd, Genzyme Corp, Gilead Sciences, Given Imaging, GlaxoSmithKline, Human Genome Sciences, Ironwood Pharmaceuticals, Janssen Pharmaceutical Research & Development, LLC, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Lycera Corp, Meda Pharmaceuticals, Merck Research Laboratories, Merck Serono, Millennium Pharmaceuticals, Nisshin Kyorin Pharmaceuticals, Novo Nordisk, NPS Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics, Inc, PDL Biopharma, Pfizer Inc, Procter and Gamble, Prometheus Laboratories, ProtAb, Ltd, Purgenesis Technologies, Inc, Relypsa, Inc, Roche, Salient Pharmaceuticals, Salix Pharmaceuticals, Santarus, Schering Plough, Shire Pharmaceuticals, Sigmoid Pharma, Ltd, Sirtris Pharmaceuticals, SLA Pharma UK, Ltd, Targacept, Teva Pharmaceuticals, Therakos, Tilliotts Pharma AG, TxCell SA, UCB Pharma, Viamet Pharmaceuticals, Vascular Biogenics, Ltd, Warner Chilcott UK, Ltd, and Wyeth; has received research grants from Abbott, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen Pharmaceutical Research & Development, LLC, Millennium Pharmaceuticals, Novartis, Pfizer Inc, Procter and Gamble, Shire Pharmaceuticals, and UCB Pharma; has received payments for lectures and speakers bureau fees from Abbott, Bristol-Myers Squibb, and Janssen Pharmaceutical Research & Development, LLC; and holds stock/stock options in Enteromedics. Subrata Ghosh has received consulting fees from Abbott, Pfizer Inc, Merck, Shire, Centocor, and BMS; has received research grants from Merck and Abbott; has received payment for lectures from Abbott, Merck, Shire, Millennium, Centocor, and Ferring; and has received payment for the development of an educational presentation from Abbott. Julian Panes has received speaker fees from AbbVie, MSD, Shire Pharmaceuticals, and UCB; has acted as a scientific consultant for AbbVie, Bristol-Myers Squibb, Ferring, MSD, Novartis, Pfizer Inc, Shire Pharmaceuticals, Tygenics, and UCB; and has received research grants from AbbVie and MSD. Ivana Vranic, Wenjin Wang, and Wojciech Niezychowski are employees of, and hold stock/stock options in, Pfizer Inc.
Funding This study was sponsored by Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications , funded by Pfizer Inc .